Schizophrenia drug patent survives Section 101 test at Federal Circuit
19 April 2018
|
Michael Loney, New York
In its important Vanda Pharmaceuticals v West-Ward Pharmaceuticals opinion, the Federal Circuit found the claims eligible at step two of the Mayo/Alice test whereas the district court found them eligible at step one
The Federal Circuit has affirmed a
ruling of patent eligibility in
Vanda Pharmaceuticals v West-Ward Pharmaceuticals for
claims directed to a drug based upon the results of a
diagnostic technique.
The patent is owned by Aventisub and exclusively licensed
to...
Please
log in to read the rest of this article.
New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Already registered?
Please make sure you log in to read the rest of the article.
Log in
Join us now
Gain FREE access to up to five free articles when you register now. Join here